An industry team consisting of Battelle, Andelyn Biosciences and AmplifyBio has secured a position on an eight-year, $149 million contract vehicle to provide support services for a National Institutes of Health research program focused on the development of treatments for neurological conditions.
The Central Ohio-based team will provide nonclinical and manufacturing support to help the National Institute of Neurological Disorders and Stroke advance the translational development of biological treatments under the multiple-award, indefinite-delivery/indefinite-quantity contract, Battelle said Friday.
“The contract will be used to advance innovative therapies, including cell and gene therapy, for a broad variety of neurological diseases,” said Drew Cawthon, business line director for Battelle’s life science research.
Jerry Hacker, executive vice president and chief commercial officer at AmplifyBio, said the company looks forward to contributing its preclinical study and therapy analytics capabilities to pursue the development of treatments for neurological conditions.
Battelle brings to the partnership its decades of experience in federal government contracting and assay and integration services to support regulatory approvals.
